Skip to Content

Advaxis Lead Drug ADXS11-001 Well-Tolerated in 72 Patients, to Date

Advaxis EVP of Science and Operations Updated Clinical Trial Safety Findings at Target Meeting Webinar

PRINCETON, N.J.--(BUSINESS WIRE)--Apr 18, 2011 - Dr. John Rothman, EVP of Science and Operations at Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, gave the lead presentation entitled, “The Use of Live Attenuated Listeria that Express LLO-Antigen Fusion Proteins for the Treatment of Cancer” in a Target Meeting webinar held April 16, 2011 entitled “Immunotherapy: a promising way for cancer treatment.”

In his presentation, he reported:

a. Advaxis has treated 72 patients with 180 doses of live attenuated Listeria safely, to-date

b. Drug-related side effects have been infrequent and are typically mild to moderate when they occur

c. When side effects have occurred, they have been treated symptomatically and have not required antibiotics – indicating that the side effects are not related to the onset of Listerial disease but result from strong innate immune stimulation which causes a flu-like syndrome of fever and chills and occasionally nausea.

Of note, Dr. Rothman cited how unusual Listerial disease is; with there being fewer than 800 cases in the world literature over the past 50+ years.

“What we witnessed in the clinic confirms the data in the laboratory,” Dr. Rothman told the scientific audience. “We have developed strains of Listeria that can be given to mice in doses 100,000 times greater than the normally lethal levels of the wild type bacterium without any animals dying. Our experience with end-stage cancer patients using our attenuated Listeria indicates that they can be given safely even to those who have very weakened immune systems.”

About Target Meeting

Target Meeting is a leading online meeting organizer for life science conferences, dedicated to high quality innovative research communication for life science researchers, students, professors, and professionals. For more information, please visit

About Advaxis Incorporated

Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by Dr. Yvonne Paterson at The University of Pennsylvania. Today, the Company has over nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company's portals: | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.


Contact: Advaxis Incorporated
Conrad F. Mir, 609-452-9813 (Office)
Executive Director
Diana Moore


Posted: April 2011